September 2026
Added to Dediabetes Sep 12, 2026RCTs
This study investigated the effects of Liraglutide and Empagliflozin on left atrial function in individuals with type 2 diabetes, finding significant improvements in left atrial reservoir strain.
Interventions
Basal insulinCombination of Liraglutide and EmpagliflozinEmpagliflozin+1 more
Outcomes
Femoral-ankle pulse wave velocity (faPWV) during acute hyperglycemiaHbA1cLeft atrial reservoir strain (LASr_ED)+1 more
Added to Dediabetes Sep 12, 2026RCTs
This study evaluated the pancreatic safety of Dulaglutide in Chinese patients with Type 2 Diabetes, finding no significant changes in pancreatic enzyme levels.
Outcomes
Pancreatic amylaseSerum Amylase LevelsSerum Lipase Levels
Added to Dediabetes Sep 12, 2026RCTs
The SEPRA trial compared once-weekly subcutaneous semaglutide to standard care in adults with type 2 diabetes, assessing various health outcomes.
Interventions
Subcutaneous Semaglutide
Outcomes
Frequency of physician visitsGlycemic control (standard of care)Patient-reported outcomes+2 more
Added to Dediabetes Sep 12, 2026RCTs
This study evaluated the effects of liraglutide and sitagliptin on hepatic steatosis and fibrosis in type 2 diabetes but found no significant reductions.
Interventions
LiraglutideSitagliptin
Added to Dediabetes Sep 12, 2026RCTs
A twelve-month treatment with dulaglutide and dapagliflozin significantly improved arterial stiffness and reduced albuminuria in patients with type 2 diabetes.
Interventions
Combination of dulaglutide and dapagliflozinDipeptidyl peptidase-4 inhibitors
Outcomes
Femoral-ankle pulse wave velocity (faPWV) during acute hyperglycemiaGlobal longitudinal strainReduction in Perfused Boundary Region (PBR) at 12 months+2 more
Added to Dediabetes Sep 12, 2026RCTs
This study compared exenatide and insulin glargine in patients with Type 2 diabetes inadequately controlled by metformin, finding significant reductions in blood glucose levels with both treatments.
Interventions
ExenatideInsulin therapy
Outcomes
1/HOMA-IRAmplitudeBlood glucose+8 more
Added to Dediabetes Sep 12, 2026RCTs
This study evaluated the effects of liraglutide on glycaemic control in patients with Type 2 diabetes inadequately managed with SGLT2 inhibitors, finding significant improvements in HbA1c levels.
Outcomes
Body weightHbA1cProportion achieving HbA1c <7.0%+1 more
Added to Dediabetes Sep 12, 2026RCTs
This study compared the metabolic effects of liraglutide and glimepiride in type 2 diabetes patients, finding greater reductions in several lipid markers with liraglutide.
Interventions
GlimepirideLiraglutide
Outcomes
HDL cholesterolLDL cholesterolLysophosphatidylcholine+5 more
Added to Dediabetes Sep 12, 2026RCTs
This study evaluated the non-inferiority of Intas semaglutide compared to innovator semaglutide in patients with type 2 diabetes.
Outcomes
BMIBody weightFasting Blood Glucose (FBG)+3 more
Added to Dediabetes Sep 12, 2026RCTs
The SEESAW trial investigated the effects of empagliflozin and dietary energy restriction on various appetite-related hormones in individuals with type 2 diabetes.
Interventions
Empagliflozin
Outcomes
GLP-1Lower PYY concentration after M-meal in T2D patientsSubjective appetite ratings after MCT and WPI preloads+1 more
